Introduction
Apoptosis is a type of physiologic cell death characterized by chromatin condensation, DNA fragmentation and membrane blebbing (Kerr and Harmon, 1991) . Various stimuli, such as ligation of death receptors, Fas and Type I TNF receptor (p55TNFR), by their ligands and withdrawal of growth factors trigger apoptosis in a variety of cell systems (Beyaert and Fiers, 1994; Baker and Reddy, 1996; Fraser and Evan, 1996) . In addition to such physiologic stimuli, anticancer drugs induce apoptosis in cancer cells, indicating that apoptosis could play a role in anticancer chemotherapy Chen et al., 1996; Mashima et al., 1995a,b) .
To study the mechanism of drug-induced apoptosis, we have developed and characterized several apoptosisresistant variant cell lines from human monocytic leukemia U937 cells. One of the mutant, UK711, shows resistance to apoptosis induced by anticancer drugs such as etoposide, Ara-C, Adriamycin and camptothecin but not by TNF-a and anti-Fas antibody. Since etoposide caused comparable DNA double-strand breaks in UK711 cells, the resistant cells could be functionally defective in recognizing DNA breaks or in subsequently transducing apoptotic signals (Kataoka et al., 1994) . We also isolated another type of apoptosis-resistant variant, UK110, that shows selective resistance to TNF-a-and anti-Fas-induced apoptosis but not to anticancer drug-induced apoptosis (Noguchi et al., 1995) . The UK110 cells have a functional mutation in a gene on chromosome 22 and can not transduce Fas-and p55TNFR-mediated apoptotic signals to activate CPP32, an ICE family protease involved in U937 apoptosis (Noguchi et al., 1996) .
In this study, we developed a novel variant, UC, showing resistance to apoptosis induced by TNF-a, anti-Fas and anticancer drugs such as etoposide and Ara-C. The mechanistic analysis showed that c-Myc expression is reduced in the UC cells compared with the parental U937 cells. The role of the c-Myc expression in the anticancer drug-induced apoptosis as well as in death receptor-mediated apoptosis was studied.
Results
Resistance of UC cells to apoptosis induced by TNF-a, anti-Fas and anticancer drugs U937 cells were mutated by EMS treatment and induced to undergo apoptosis by TNF-a. The surviving cells were cloned by limiting dilution and analyzed for their resistance to apoptosis. We obtained several apoptosis-resistant variants. Among them, a mutant cell line named UC showed resistance to apoptosis induced by the anticancer drugs etoposide and Ara-C and by TNF-a and anti-Fas antibody, as indicated by reduced DNA fragmentation into an oligonucleosomal ladder (Figure 1a. ). The apoptosisresistance in UC cells was also demonstrated by¯ow- and UC cells treated with TNF-a (10 ng/ml), anti-Fas Ab (300 ng/ml)/CHX (1 mg/ml), VP-16 (10 mg/ml) and Ara-C (10 mg/ml) for the indicated times. (b) Flow cytometric analysis of apoptosis development in U937 and UC cells after treatment with TNF-a (0.3 ng/ml)/CHX (1 mg/ml), anti-Fas Ab (300 ng/ml)/ CHX (1 mg/ml), VP-16 (10 mg/ml) for 4 h and Ara-C (10 mg/ml) for 5 h. cytometric analysis (Figure 1b) . Consistent with the reduced apoptotic population in UC cells, their viability was higher than that of the parental U937 cells after TNF-a or etoposide treatments ( Figure 1c ). These results indicate that UC cells show resistance to death receptor-mediated and chemotherapy-induced apoptosis.
Somatic cell hybridization of UC and U937 cells
To examine whether the apoptosis-resistant phenotype in UC was genetically dominant or recessive, we carried out somatic cell hybridization between UC and the parental U937 cells. When cells were treated with TNF-a for 24 and 48 h, the viability of the hybrid was comparable to that of the U937 cells (Figure 2a ). This result indicates that the apoptosis-resistance against TNF-a in UC was genetically recessive. The hybrid cells, however, showed apoptosis-resistance against etoposide, as did UC cells (Figure 2b ), indicating that the resistance against etoposide was genetically dominant. These results suggest that UC has, at least, two functional mutations; one is a recessive mutation resulting in resistance against TNF-a, and the other one is a dominant mutation that confers resistance against etoposide.
Expression of apoptosis-related proteins in UC cells
Since TNF-a and anti-Fas antibody trigger apoptosis by binding to cell surface receptors on target cells (Yonehara et al., 1989; Suda et al., 1993; Tartaglia et al., 1993; Nagata and Golstein, 1995) , the expression of the death receptors was examined in U937 and UC cells. Both cell lines express comparable amounts of p55TNFR and Fas antigen (Figure 3a) . These results suggest that UC was mutated in an apoptosis signal pathway after binding of death ligands with the receptors. Overexpression of anti-apoptotic proteins, such as Bcl-2 and Bcl-x L , is reported to suppress apoptosis induced by most stimuli (Bissonnette et al., 1992; Boise et al., 1993) . UC cells, however, expressed equal amount of Bcl-2 (Figure 3b ) and Bcl-x L (not shown), as compared with U937 cells. We also examined the expression of pro-apoptotic Bcl-2 family proteins, such as Bax, Bak and Bad (Oltvai et al., 1993; Chitteaden et al., 1995; Yang et al., 1995) , but we found no changes in the expression levels of these proteins in UC cells (not shown).
We further examined the expression of proteins known to be involved in apoptosis and found that cMyc expression (Evan et al., 1992) is signi®cantly reduced in UC cells (Figure 3c ). c-Myc protein is reported to regulate cell cycle progression (Amati et al., 1993) . UC cells, however, proliferate as well as U937 cells do, and cell cycle phase distribution of UC cells was almost comparable to that of U937 cells (not shown).
Restoration of sensitivity to death receptor-mediated apoptosis by c-myc transfection
Since c-Myc expression was reduced in UC cells, we transfected the c-myc gene into the UC cells and examined their sensitivity to apoptosis. We could obtain two independent transfectant clones, I-10 and III-4, that restore c-Myc expression to a level slightly less than in the parental U937 cells (Figure 4a ). These transfectants showed increased sensitivity to TNF-ainduced apoptosis over UC and UC/mock transfectant ( Figure 4b The clone III-4 showed restored sensitivity to antiFas-induced apoptosis as well as to TNF-a-induced apoptosis, as determined by DNA fragmentation analysis ( Figure 5a ). Consistently, the viability of the clone III-4 after TNF-a and anti-Fas treatment was less than that of the UC/mock cells ( Figure 5b ).
We further examined the processing of CPP32 in the transfectant, since its activation plays a key role in U937 apoptosis (Schlegel et al., 1996; Mashima et al., 1997; Seimiya et al., 1997) . When cells were treated with TNF-a, a p17 fragment of CPP32 appeared in U937 and the clone III-4 cells but not in UC/mock cells ( Figure 6 ). This result indicates that CPP32 activation after TNF-a treatment is restored in the clone III-4, much like the cellular sensitivity to TNF-ainduced apoptosis in this cell line.
All the above results indicate that c-myc transfection into UC cells restores sensitivity to TNF-a-and antiFas-induced apoptosis. This suggests that the reduced c-Myc expression in UC was the recessive mutation resulting in resistance to death receptor-mediated apoptosis.
Resistance of c-myc-transfected UC cells to chemotherapy-induced apoptosis.
In contrast to the restored sensitivity to death receptormediated apoptosis, the c-myc-transfected UC clones, I-10 and III-4, showed resistance to etoposide-induced apoptosis (Figure 4b ). DNA fragmentation analysis showed that III-4 was resistant to etoposide-and Ara-C-induced apoptosis but showed restored sensitivity to TNF-a-and anti-Fas-induced apoptosis (Figure 5a ). The viability of III-4 was higher than UC/mock cells when the cells were treated with graded concentrations of etoposide and Ara-C (Figure 5b ). In addition, CPP32 processing to the p17 fragment by etoposide was abrogated in the III-4 clone ( Figure 6 ). These observations may argue against the role of c-Myc in chemotherapy-induced apoptosis in U937 cells. UC cells, however, could have an additional mutation that confers resistance to etoposide-induced apoptosis in a genetically dominant manner. Therefore, we further examined the role of c-Myc in etoposideinduced apoptosis in U937 cells using a c-myc antisense oligonucleotide. (Figure 7b) . Consistently, the viability of the antisense-treated cells was higher than untreated or sensetreated U937 cells after TNF-a and etoposide treatments (Figure 7c ). These results indicate that cMyc plays a role in etoposide-induced apoptosis as well as in TNF-a-induced apoptosis.
Discussion
In this study, we developed UC cells that showed resistance to apoptosis induced by TNF-a, anti-Fas antibody, etoposide and Ara-C. The somatic cell hybridization analysis showed that the apoptosisresistance to TNF-a in UC was genetically recessive and the resistance to etoposide was dominant, indicating UC had at least two mutations functionally involved in apoptosis. UC cells expressed reduced amounts of c-Myc as compared with the parental U937 cells, and c-Myc transfection into UC cells restored sensitivity to TNF-a and anti-Fas-induced apoptosis. These results indicate that the apoptosis-resistance to TNF-a and anti-Fas in UC cells is attributed to the reduced expression of c-Myc. By contrast, c-myc transfection into UC cells could not restore their sensitivity to etoposide-and Ara-C-induced apoptosis.
The experiment with antisense oligonucleotides designed to reduce c-Myc expression revealed that the reduction could render U937 cells resistant to etoposide-induced and TNF-a-induced apoptosis. This result suggests that the reduced c-Myc expression in UC could also be associated with the resistance to etoposide-induced apoptosis. The inability of c-myc transfection to restore UC cell sensitivity to etoposideinduced apoptosis could be explained by the fact that the UC cells contain a second mutation that confers genetically dominant resistance to etoposide-induced apoptosis. The dominant mutation responsible for the resistance to etoposide-induced apoptosis is unidenti®ed at present. The signi®cant role of c-Myc in TNF-a-induced cytotoxicity has been suggested previously in HeLa cells (Janicke et al., 1994) . A TNF-a-resistant variant of HeLa cells expressed reduced amounts of c-Myc compared with the TNF-a-sensitive line and the reduction of c-Myc expression by antisense oligonucleotides treatment render the sensitive cells more resistant to TNF-a cytotoxicity. Janicke et al. (1994) , however, did not demonstrate restoration of TNF-a sensitivity by increased expression of c-Myc in the resistant variant. Another study showed that increased c-Myc expression in ®broblasts enhanced the cellular sensitivity to TNF-a cytotoxicity (Klefstrom et al., 1994) . Our present results are consistent with these reports and convincingly demonstrated the role of cMyc in death receptor-mediated apoptosis in U937 cells. Additionally, the restoration of CPP32 activation by c-myc transfection into UC cells indicates that cMyc plays a role at a step upstream of CPP32 activation in apoptosis development.
The role of c-Myc in the cellular sensitivity to anticancer drugs is still obscure. Some papers report Involvement of c-Myc in TNF-a and drug-induced apoptosis J Dong et al that increased c-Myc expression enhances cellular sensitivity to anticancer drugs (Lotem and Sachs, 1993; Fujita and Shiku, 1995) . On the other hand, another paper reports that the viability of ®broblasts treated with anticancer drugs increased by expression of a transfected c-myc gene (Niimi et al., 1991) . Yet another report suggests the questionable role of c-Myc in drug-induced cell death (Wood et al., 1995) . Thus, the role of c-Myc in susceptibility to drug-induced cell death remains controversial. Our data suggest that the reduction of c-Myc expression by treating U937 cells with antisense oligonucleotides suppressed etoposide- 
Materials and methods

Chemicals and antibodies
Recombinant human TNF-a was purchased from Genzyme Corp. (Cambridge, MA). Anti-Fas Ab, clone CH-11, and UB2 were purchased from Medical & Biological Laboratories Co. Ltd. (Nagoya, Japan). Agonistic anti-p55TNFR Ab was obtained from R&D systems (Minneapolis, MN) . Anti-c-Myc Ab (clone 9E10) was purchased from Oncogene Science, Inc. (Uniondale, NY), anti-human Bcl-2 Ab (clone 124) from Boehringer-Mannheim (Mannheim, Germany), and anti-CPP32 Ab from Transduction Laboratories (Lexington, Kentucky). Geneticin, Ara-C, EMS and cycloheximide (CHX) were purchased from Sigma Chemical Company (St. Louis, MO). Etoposide was from Brystol Meyers-Squibb, Ltd., Tokyo, Japan. pSV2bsr and blasticidin S were purchased from Funakoshi Co. Ltd., Tokyo, Japan. The phosphorothioate antisense and sense oligonucleotide were synthesized by BEX Co. Ltd., Tokyo, Japan. The antisense c-myc oligonucleotide AACGTTGAGGGG-CAT covered the ®rst ®ve codons of exon 2.
Cell line and cell culture
Human U937 monocytic leukemia cells were obtained from the Japanese Cancer Research Resources Bank, Tokyo, Japan. The cells were grown in RPMI 1640 (Nissui Co. Ltd., Tokyo, Japan) supplemented with 10% heatinactivated fetal bovine serum and 100 mg/ml of kanamycin (RPMI growth medium) in a humidi®ed atmosphere of 5% CO 2 and 95% air. All experiments were performed using cells in their exponential growth phase.
Mutagenesis and screening
Mutagenesis was performed basically as described (Kataoka et al., 1994) . Brie¯y, U937 cells (2610 6 ) were treated with 30 mg/ml of ethyl methanesulfonate (EMS) for 24 h at 378C. EMS was removed by washing with PBS, then cells were recovered for 6 days at 378C. The mutagenized cells (10 7 ) were exposed to 3 ng/ml TNF-a and 1 mg/ml CHX for 6 h and incubated for 5 days at 378C. The surviving cells were cloned by limiting dilution, and variant clones that showed resistance to apoptosis were selected. One of these clones, UC, was used for further experimentation. UC was cultured in growth medium (RPMI 1640 containing 10% heat-inactivated fetal bovine serum) without TNF-a, and the resistant phenotype of UC cells was stable for at least 6 months.
Detection of p55TNF receptor and Fas antigen
To examine the expression of cell surface molecules, cells were washed with PBS and suspended at 10 6 cells/60 ml in RPMI 1640 medium containing 0.2% BSA and 10 mg/ml of antibodies (anti-p55TNFR and anti-Fas Ab). Cells were incubated on ice water for 1 h, washed with PBS, and reacted with¯uorescein-conjugated second antibodies for 45 min in ice water. After washing with PBS, the expressions of p55TNFR and Fas were analysed usinḡ ow cytometry (FACScan; Becton Dickinson, Braintree, MA).
Drug treatment
U937 and UC cells were treated with indicated concentrations of TNF-a, anti-Fas antibody and anticancer drugs. In some experiments, CHX was added to the culture since CHX enhances TNF-a-and anti-Fas-induced apoptosis. UC cells showed resistance to TNF-a-and anti-Fasinduced apoptosis regardless of CHX presence. The dose of TNF-a varied depending on the presence or absence of CHX.
Analysis of DNA fragmentation
DNA fragmentation was analysed as described with slight modi®cations (Kataoka et al., 1994) . U937 and UC cells (5610 5 ) were suspended in 20 ml of 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 0.5 mg/ml proteinase K (Sigma). After incubation at 508C for 2 h, a 10-ml aliquot of 0.5 mg/ml RNase A solution was added, and the mixture was incubated for an additional 2 h. The sample was mixed with 10 ml of preheated (708C) 10 mM EDTA solution (pH 8.0) containing 1% (w/v) low-melting-point agarose (Sigma), 0.25% bromphenol blue, and 40% sucrose. DNA was analyzed by electrophoresis in 2% agarose gels followed by ethidium bromide staining and was then photographed on a u.v. illuminator.
Measurement of apoptosis by¯ow cytometer
Cells (5610 5 cells/ml) were treated with the indicated concentrations of TNF-a, anti-Fas antibody and antitumor agents. After incubation for the indicated times, cells were harvested and ®xed in 70% ethanol for 30 min on ice. Following treatment with RNase A for 30 min at 378C, cells were stained in propidium iodide solution (50 mg/ml in 0.1% sodium citrate, 0.1% NP-40). The stained cells were analysed using a FACScan¯ow cytometer.
Immunoblot analysis
The cellular extracts for c-Myc, CPP32 and Bcl-2 Western blot analysis were prepared as described below. After washing with PBS, cells were lysed in lysis buer for cMyc, CPP32 and Bcl-2 (2% NP40, 0.5% sodium deoxycholate, 0.2% SDS, 25 mM Tris-HCl, 50 mM NaCl, 1 mM PMSF, pH 8.0) for 15 min on ice, cleared by centrifugation, and stored at 7808C. The protein concentration was determined using BCA protein reagents (Pierce, Rockford, IL). The cell lysates (20 mg) were subjected to SDS ± PAGE and electroblotted to a nitrocellulose membrane (Schreicher & Schuell, Dasse, Germany). The blotted membrane was blocked and reacted with each of the ®rst antibodies. After washing, the membrane was reacted with horseradish peroxidaseconjugated second antibodies. Antibody-bound antigens were detected using an ECL detection system (Amersham International, Buckinghamshire, United Kingdom) and recorded on Kodak X-Omat ®lm (Kodak, Rochester, NY).
Cell survival assay
Cells were treated by adequate stimulus in a 96-microwell plate. After the appropriate time, viable cells were counted by trypan blue dye exclusion assay. The viable cell number without treatment was expressed as 100% control.
Cell fusion
Transfection of the pSV2bsr into UC cells was performed by electroporation. U937/Neo cells were developed by infecting U937 cells with a pLXSN-neo retrovirus produced from PA317 cells (Miller and Rosman, 1989) . After selection by blasticidin S (3 mg/ml) or geneticin (400 mg/ml), resistant populations (geneticin-resistant U937/neo and blasticidin S-resistant UC/bsr) were fused by the polyethylene glycol method, as described (Fujita et al., 1993) . The fused cells were subjected to double-drug selection (3 mg/ml blasticidin S hydrochloride and 400 mg/ ml geneticin) for several weeks, and the surviving hybrid cells were used as U9376UC hybrid.
Transfection of the c-myc Gene
A full length c-myc gene (Japan Cancer Research Resources Bank) was inserted directly into EcoRI site of the eukaryotic cell expression vector pcDNA3 (Invitrogen, San Diego, CA). pcDNA3/c-myc was transfected into UC cells by electroporation (960 mF, 220 V) (Gene Pulser TM ; Bio-Rad, Richmond, CA). After 2 days of incubation, the cells were exposed to 800 mg/ml of G418, and G418-resistant cells were subsequently cloned. Then, expression of c-Myc in the transfectant clones was examined, and two independent clones were obtained. The successful transfection of the c-myc gene into the transfectants was con®rmed by Southern blot analysis, as described previously (Mikami et al., 1996) .
c-myc antisense oligonucleotides treatment
The oligonucleotides were dissolved in 30 mM HEPES (pH 7.0) and added to the culture medium at 50 mM. After 48 h, c-Myc expression was examined by immunoblot. The treated cells were incubated with the indicated concentrations of TNF-a or etoposide for further 24 h to determine TNF-a and etoposide cytotoxicity, as described above.
